Product correctly added to cart.

discount label
H-KSPWFTTL-OH
View 3D

Biosynth logo

H-KSPWFTTL-OH

Ref. 3D-PP44136

1mg
202.00 €
10mg
234.00 €
100mg
412.00 €
Estimated delivery in United States, on Friday 27 Dec 2024

Product Information

Name:
H-KSPWFTTL-OH
Synonyms:
  • NH2-Lys-Ser-Pro-Trp-Phe-Thr-Thr-Leu-OH
Description:

Peptide H-KSPWFTTL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KSPWFTTL-OH include the following: Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape WR Green - Immunological reviews, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-065X.1999.tb01298.x The role of proximal and distal sequence variations in the presentation of an immunodominant CTL epitope encoded by the ecotropic AK7 MuLV V Kim, WR Green - Virology, 1997 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S004268229798747X A single amino acid variation within an immunodominant AKR/Gross MuLV cytotoxic T-lymphocyte epitope leads to a loss in immunogenicity V KIM, WR GREEN - Viral Immunology, 1998 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.1998.11.197 Naturally occurring TAP-dependent specific T-cell tolerance for a variant of an immunodominant retroviral cytotoxic T-lymphocyte epitope V Kim, JW Yewdell , WR Green - Journal of Virology, 2000 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.74.8.3924-3928.2000 Cytolytic T lymphocyte responses to AKR/gross murine leukemia virus induced tumors V Kim - 1999 - search.proquest.comhttps://search.proquest.com/openview/ccc7f748a4261aa7ffc90fa75060d4ea/1?pq-origsite=gscholar&cbl=18750&diss=y Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen S Zhou , Y Song , Y Luo , B Quinn, Y Jiao, MD Long - Cancer Research , 2024 - AACRhttps://aacrjournals.org/cancerrescommun/article/4/4/958/742832 Apoptosis of epitope-specific antiretroviral cytotoxic T lymphocytes via Fas ligand-Fas interactions RF Rich, WR Green - Viral Immunology, 2006 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.2006.19.424 Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells RF Rich, WR Green - The Journal of Immunology, 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2751/34719 Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral RF Rich, WJ Cook, WR Green - Virology, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0042682205006574 Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region N Shimbara, H Nakajima, N Tanahashi - Genes to , 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2443.1997.1610359.x Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom , HW Nijman , R Offringa - The Journal of , 1997 - rupress.orghttps://rupress.org/jem/article-abstract/186/5/695/7269 Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity MCW Feltkamp , MPM Vierboom , WM Kast - Molecular , 1994 - Elsevierhttps://www.sciencedirect.com/science/article/pii/0161589094901554 Recognition of endogenous ecotropic murine leukaemia viruses by anti-AKR/Gross virus cytotoxic T lymphocytes (CTL): epitope variation in a CTL-resistant virus MA Coppola , TM Lam - Journal of general , 1995 - microbiologyresearch.orghttps://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-76-3-635 Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes M Lucchiari-Hartz, PM Van Endert , G Lauvau - The Journal of , 2000 - rupress.orghttps://rupress.org/jem/article-abstract/191/2/239/50980 NK cell transfer overcomes resistance to PD-(L) 1 therapy in aged mice J Hou, S Xie, J Gao, T Jiang, E Zhu, X Yang - Hematology & Oncology, 2024 - Springerhttps://link.springer.com/article/10.1186/s40164-024-00511-9 Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy J Dubrot, A Palazon , C Alfaro - journal of cancer, 2011 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25333 Wnt3a neutralization enhances T-cell responses through indirect mechanisms and restrains tumor growth I Pacella, I Cammarata, C Focaccetti, S Miacci - Cancer Immunology , 2018 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/6/8/953/469079 Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12 I Melero, JI Quetglas, M Reboredo, J Dubrot - Cancer research, 2015 - AACRhttps://aacrjournals.org/cancerres/article-abstract/75/3/497/606515 High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy HJ Zeh , D Perry-Lalley, ME Dudley - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/162/2/989/31612 An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores HD White , DA Roeder, WR Green - Journal of virology, 1994 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.68.2.897-904.1994 Integrating CD4+ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model H Shibata, N Xu, S Saito, L Zhou , I Ozgenc - , 2021 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2021.1958589 A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation F Ossendorp , M Eggers, A Neisig, T Ruppert - Immunity, 1996 - cell.comhttps://www.cell.com/trends/immunology/fulltext/S1074-7613(00)80488-4 Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers EC Moore, HA Cash, AM Caruso, R Uppaluri - Cancer immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/4/7/611/468556 Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy C He , X Duan , N Guo, C Chan, C Poon - Nature , 2016 - nature.comhttps://www.nature.com/articles/ncomms12499 Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type AJ Sijts , F Ossendorp , EA Mengede - (Baltimore, Md.: 1950 , 1994 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/152/1/106/25902 Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection AA McCormick, TA Corbo, S Wykoff-Clary - Bioconjugate , 2006 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/bc060124m TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models AA McCormick, TA Corbo, S Wykoff-Clary, LV Nguyen - Vaccine, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X06007079

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-PP44136 H-KSPWFTTL-OH

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".